Hope Pharmaceuticals Files Supplemental New Drug Application to the Food and Drug Administration for Sodium Thiosulfate Injection
For Immediate Release: June 7, 2018
Media Inquiries: Craig Sherman, M.D.
(480) 607-1970 or [email protected]
Scottsdale, Arizona June 7, 2018 – Hope Pharmaceuticals today announced that the company filed a Supplemental New Drug Application to the United States Food and Drug Administration (FDA) for the use of Sodium Thiosulfate Injection to prevent a potential complication associated with the administration of a chemotherapeutic agent.
Hope Pharmaceuticals’ Sodium Thiosulfate Injection has already been approved by the FDA as an antidote for acute cyanide poisoning that is judged to be life-threatening and is currently distributed in the United States in individually-packaged 50 mL vials.
Additional information about Sodium Thiosulfate Injection is available online at www.thiosulfate.info.
Hope Pharmaceuticals is a privately owned company located in Scottsdale, Arizona.
####
